TKMR Share Price

Open 3.15 Change Price %
High 3.25 1 Day 0.10 3.17
Low 3.15 1 Week 0.58 21.72
Close 3.25 1 Month 0.50 18.18
Volume 322612 1 Year -1.42 -30.41
52 Week High 5.48
52 Week Low 2.45
TKMR Important Levels
Resistance 2 3.34
Resistance 1 3.30
Pivot 3.22
Support 1 3.20
Support 2 3.16
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)

TKMR Technical Analysis 1.5
As on 9th Dec 2016 TKMR Share Price closed @ 3.25 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.71 & Buy for SHORT-TERM with Stoploss of 3.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
TKMR Target for December
1st Target up-side 3.06
2nd Target up-side 3.35
3rd Target up-side 3.63
1st Target down-side 2.24
2nd Target down-side 1.95
3rd Target down-side 1.67
TKMR Other Details
Segment EQ
Market Capital 59253228.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TKMR Address
TKMR
N/A
Interactive Technical Analysis Chart Tekmira Pharmaceuticals Corp ( TKMR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tekmira Pharmaceuticals Corp
TKMR Business Profile
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.